{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adult+Solid+Neoplasm&page=27", "query": { "condition": "Adult Solid Neoplasm", "page": 27 }, "page_size": 10 }, "pagination": { "page": 27, "page_size": 10, "total_count": 1462, "total_pages": 147, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adult+Solid+Neoplasm&page=28&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Adult+Solid+Neoplasm&page=26&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-25T10:06:15.956Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04130516", "title": "Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult" ], "interventions": [ { "name": "LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER", "type": "DRUG" }, { "name": "Pembrolizumab - anti-PD-1 antibody", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Linnaeus Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2019-10-21", "completion_date": "2026-08-15", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-10-25T10:06:15.956Z", "location_count": 10, "location_summary": "Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04130516" }, { "nct_id": "NCT06777316", "title": "A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Intrahepatic Cholangiocarcinoma (Icc)", "Cholangiocarcinoma", "Other Solid Tumors, Adult", "FGFR2 Gene Fusion/Rearrangement", "FGFR2 Gene Amplification", "FGFR2 Gene Short Variants", "FGFR3 Gene Fusion/Rearrangement", "FGFR3 Gene Amplification", "FGFR3 Gene Short Variants", "FGFR2 Genetic Alterations", "FGFR3 Genetic Alterations", "Advanced Solid Tumors" ], "interventions": [ { "name": "CGT4859", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cogent Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2025-01-22", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-04-17", "last_synced_at": "2026-10-25T10:06:15.956Z", "location_count": 12, "location_summary": "Palo Alto, California • Jacksonville, Florida • Tampa, Florida + 9 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06777316" }, { "nct_id": "NCT00878904", "title": "Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "epirubicin hydrochloride", "type": "DRUG" }, { "name": "panobinostat", "type": "DRUG" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "protein expression analysis", "type": "GENETIC" }, { "name": "western blotting", "type": "GENETIC" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 40, "start_date": "2009-09-13", "completion_date": "2016-10-10", "has_results": false, "last_update_posted_date": "2017-03-24", "last_synced_at": "2026-10-25T10:06:15.956Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00878904" }, { "nct_id": "NCT01096381", "title": "Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer", "Cardiovascular Complications", "Colorectal Cancer", "Fallopian Tube Cancer", "Head and Neck Cancer", "Lung Cancer", "Ovarian Cancer", "Peritoneal Cavity Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2010-03", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2012-02-27", "last_synced_at": "2026-10-25T10:06:15.956Z", "location_count": 2, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01096381" }, { "nct_id": "NCT04238819", "title": "A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed Solid Tumor", "Refractory Solid Tumor" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Dinutuximab", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 47, "start_date": "2020-11-09", "completion_date": "2025-08-19", "has_results": true, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-10-25T10:06:15.956Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Los Angeles, California • Oakland, California + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "Santa Clara", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04238819" }, { "nct_id": "NCT00320073", "title": "Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "pemetrexed disodium", "type": "DRUG" }, { "name": "vinflunine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2006-08", "completion_date": "2010-01", "has_results": false, "last_update_posted_date": "2012-05-16", "last_synced_at": "2026-10-25T10:06:15.956Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00320073" }, { "nct_id": "NCT05147272", "title": "Study of RP-6306 With Gemcitabine in Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Tumor" ], "interventions": [ { "name": "RP-6306 (oral PKMYT1 inhibitor)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Debiopharm International SA", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2021-12-16", "completion_date": "2024-08-28", "has_results": true, "last_update_posted_date": "2025-12-05", "last_synced_at": "2026-10-25T10:06:15.956Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT05147272" }, { "nct_id": "NCT00093730", "title": "BMS-599626 in Treating Patients With Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "BMS-59926", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2004-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-10-04", "last_synced_at": "2026-10-25T10:06:15.956Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00093730" }, { "nct_id": "NCT00860041", "title": "Acute Pain Caused by Paclitaxel in Patients With Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chemotherapeutic Agent Toxicity", "Neurotoxicity", "Pain", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "pain questionnaires", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 306, "start_date": "2009-02", "completion_date": "2013-05", "has_results": false, "last_update_posted_date": "2016-07-14", "last_synced_at": "2026-10-25T10:06:15.956Z", "location_count": 279, "location_summary": "Aurora, Colorado • Boulder, Colorado • Colorado Springs, Colorado + 181 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00860041" }, { "nct_id": "NCT00033241", "title": "Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OSI Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-07-23", "completion_date": "2004-04-22", "has_results": false, "last_update_posted_date": "2018-01-10", "last_synced_at": "2026-10-25T10:06:15.956Z", "location_count": 2, "location_summary": "Tucson, Arizona • San Antonio, Texas", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00033241" } ] }